BIO Notebook Day 4: Waiting On Data, Adjusting To The IRA, And Focusing On All Patients

An investor and pharmaceutical executives speaking on a panel at the BIO International Convention in Boston outlined ways in which they have adjusted their investment decisions and continue to reevaluate portfolio strategies in light of the Inflation Reduction Act (IRA).

Their comments echoed concerns that others at the meeting have expressed about the IRA, signed into law last year, which includes a provision requiring the Centers for Medicare and Medicaid Services (CMS) to negotiate pricing for drugs covered by Medicare nine years after US Food